Peripheral Latanoprost Administration Lowers Intraocular Pressure in the Wistar Rat-Reference-Cited by-同舟云学术

Peripheral Latanoprost Administration Lowers Intraocular Pressure in the Wistar Rat

Published:2020-08-05 Issue:3 Volume:9 Page:1-8
ISSN:2193-8245
Container-title:Ophthalmology and Therapy
language:en
Short-container-title:Ophthalmol Ther

Author:

Świątkiewicz Maciej^ORCID,Wełniak-Kamińska Marlena^ORCID,Fiedorowicz Michał^ORCID,Kamińska Agnieszka,Rejdak Robert^ORCID,Grieb Paweł^ORCID

Funder

GBJ Pharma, Ltd., Warsaw, Poland.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

https://link.springer.com/content/pdf/10.1007/s40123-020-00256-8.pdf

Reference27 articles.

1. Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13:723–45.

2. WHO Essential Medicines and Health Products Department. World Health Organization model list of essential medicines, 21st edn. World Health Organization. 2019. https://www.who.int/medicines/publications/essentialmedicines/en/. Accessed 10 Mar 2020.

3. Klimko PG, Sharif NA. Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma. Br J Pharmacol. 2019;176: 1051–8.

4. Pfizer Inc./Pfizer Ltd. Pfizer material safety data sheet. Latanoprost solution. Pfizer Inc. 2009. https://www.pfizer.com/sites/default/files/products/material_safety_data/LATANOPROST%20SOLUTION.pdf. Accessed 08 Mar 2020.

5. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953–61.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The visual field-testing maze and vision maze: Feasible techniques to evaluate visual field loss in animals;Journal of Pharmacological and Toxicological Methods;2024-03

2. Development of the Latanoprost Solid Delivery System Based on Poly(l-lactide-co-glycolide-co-trimethylene carbonate) with Shape Memory for Glaucoma Treatment;Applied Sciences;2023-06-27

3. Changes of Ocular Dimensions as a Marker of Disease Progression in a Murine Model of Pigmentary Glaucoma;Frontiers in Pharmacology;2020-09-04